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Introduction
Malaria infection in pregnancy is a public health problem that 
poses significant risks for mothers and their unborn child1-2. 
Pregnancy reduces a woman’s immunity, hence increasing her 
vulnerability to malaria. Intermittent presumptive treatment 
in pregnancy (IPTp) of  malaria was introduced to reduce 
the burden of  malaria in pregnant women, and its resultant 
effects on the fetus3. Sulfadoxine-pyrimethamine (SP) is the 
drug currently recommended for IPTp strategy4-5. It has 
been shown to have demonstrable efficacy in preventing 
malaria in pregnancy as well as reducing placental infection 
with the parasite6. Hence, it is useful for preventing mother-
to-child transmission of  malaria and other complications 
such as severe anaemia, spontaneous abortion, stillbirth, 
premature delivery and low birth weight3. IPTp consists of  
supervised administration of  curative dose of  SP at least 
twice during the second and third trimesters of  pregnancy, 
during routinely scheduled antenatal clinic visits, regardless 
of  whether the woman is infected or not5. 
Nigeria adopted IPTp in 2005 to replace weekly prophylaxis7. 
IPTp with SP is given as a package through focused 
antenatal care and the national protocol for prevention of  
malaria specifies that it should be given free of  charge to 
pregnant women attending ANC in public health facilities 
and non-profit facilities7. The decline in efforts to scale up 
IPTp in a number of  African countries necessitated a recent 
update of  treatment protocol by World Health Organization 
(WHO)8. They observed that in high burden countries, IPTp 
noticeably lags behind other malaria control measures, hence 
the recommendation that it should be administered at every 
scheduled antenatal care visit after the first trimester at least 
one month apart9. Key barriers to the provision of  IPTp have 
been reported to be unclear policy and guidance, and service 
delivery factors such as frequent stock-out, confusion over 
timing of  each IPTp dose and introduction of  user fees10. 
Client-related factors such as poor antenatal care attendance 
also affect IPTp uptake10. It has also been suggested that 
failure of  health workers to adhere to administering IPTp 
at the appropriate gestational age contributes to low 
effectiveness of  the strategy11.
According to the 2013 DHS report of  Nigeria, 23% of  
women received SP for malaria prevention during their last 
live birth, and the trend in percentage of  women taking at 
least one dose of  SP during ANC visit increased by 22% 
from 2003 to 201312. Variations noted in the proportion of  
women using SP for malaria prevention in pregnancy were 
based on type of  place of  residence, geopolitical zone, level 
of  education and wealth quintile13. Some other studies have 
also reported these variations and inequities8,10,14-15, but only 
a few highlight the significance of  these inequities in Nigeria. 
The extent to which these characteristics influence uptake of  
IPTp with SP in pregnancy is also unclear. Additionally, there 
are other client-related and service delivery factors related to 
ANC attendance which could have significant influence on 
service utilization but are under-explored. Some studies have 
also reported that pregnant women take antimalarial drugs 
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other than SP for prophylaxis in pregnancy but this is not 
usually described in the DHS report16. This information may 
be useful for further exploratory research to guide design of  
appropriate interventions. 
This paper highlights the inequities in access to and utilization 
of  SP for malaria prophylaxis in pregnancy in Nigeria. 
It provides additional information on client-related and 
service delivery determinants of  utilization of  SP for malaria 
prophylaxis in pregnancy. This is useful for understanding 
what factors contribute to low utilization of  SP for malaria 
prophylaxis in pregnancy and could inform the development 
of  targeted interventions for scaling up coverage of  SP for 
IPTp in Nigeria.
Materials and methods
This study used secondary data from the 2013 Nigeria 
Demographic Health Survey (NDHS). The NDHS is a 
national sample survey which is conducted at five year 
intervals by the National Population Commission, within the 
months of  June and October of  the reporting year, to provide 
up to date information on demographic characteristics and 
health status of  households in Nigeria.
Nigeria country profile: 
Nigeria has an annual population growth rate of  3.2 percent 
and ranks seventh among highly populated countries in 
the world13. The constitution of  Nigeria provides for the 
operation of  three tiers of  government - the Federal, 36 
semi-autonomous States (and the Federal Capital Territory) 
and 774 local government areas grouped into six geopolitical 
zones.  In the last national census of  2006, each locality 
in Nigeria was subdivided into census enumeration areas 
determined by average number of  households13.
Primary health care is recognized nationally as the framework 
for achieving universal health care, including provision of  
maternal and child health (MCH) care at primary health 
centers12. Utilization of  services in the primary health 
facilities is limited and varies across socioeconomic and 
geopolitical differences. Ante-natal care attendance ranges 
from 31% north-east to 87% in the south-west whereas 
health facility delivery ranges from 8.4% in the north-east 
to 73% in the south-west17. On the other hand, majority of  
PHCs in the country do not run 24-hour services, thereby 
denying a lot of  patients the opportunity to patronize such 
centres when ill or for deliveries. In order to address these 
and other challenges in MCH service delivery, Nigeria 
introduced the Midwives Service Scheme (MSS) from 
2009-2011, the Subsidy Reinvestment and Empowerment 
Program (SURE-P MCH) in 2012-2015, and the most recent 
PHC revitalization in 2017, to strengthen coordination and 
improve quality of  service delivery12. 
Sampling method 
The 2013 NDHS sample was selected using a stratified three-
stage cluster design consisting of  904 clusters, 372 in urban 
areas and 532 in rural areas. The list of  census enumeration 
areas of  2006 population census formed the DHS sampling 
frame and primary sampling unit. The sample design allowed 
for specific indicators to be calculated at zonal and state 
levels. Mapping of  households was done between December 
2012 and January 2013 by trained enumerators using Global 
Positioning System (GPS) receivers. An updated list of  
households in each CEA was produced and this formed the 
sampling frame for households12. 
A fixed sample of  45 households was selected per cluster 
giving a total of  40,680 households. In each selected 
household, all reproductive aged women who were resident 
de facto were surveyed12. 
Data collection 
Two modified NDHS model questionnaires (Households 
and Women’s) were used to collect information on maternal 
and child health including antenatal care, malaria preventive 
strategies as well as other relevant health issues.
Relevant data from this study were obtained from the 
individual recode dataset for women. This dataset is generated 
using relevant information from the household and women’s 
questionnaires and contains data on intermittent preventive 
treatment for malaria during pregnancy, antenatal visits, 
type of  place of  residence (urban or rural), geopolitical 
region, asset ownership and wealth index. The women’s 
questionnaire was administered to all reproductive aged 
women in every second household in the 2013 NDHS 
sample. Questions concerning IPTp access and use were 
asked, as well as questions on frequency of  antenatal visits 
and antenatal care service provider. 
Principal component analysis based on household ownership 
of  goods, characteristics of  dwelling place, source of  
drinking water, sanitary/toilet facilities and level of  education 
of  head of  household, was used to rank households into 
socioeconomic quintiles namely: Q1 – poorest, Q2 – poorer, 
Q3 - middle, Q4 – richer, Q5 – richest.
Data analysis
DHS dataset is self-weighted by the selection of  clusters 
with probability-proportionate-to-size (PPS)12. To 
create the individual women recode dataset, data from 
household questionnaire and women’s questionnaires were 
merged. Individual responses were matched to household 
identification numbers. A total of  38,948 women were 
surveyed. A new SPSS file was created with relevant variables 
for analysis. Relevant variables were identified and their data 
extracted from the individual women recode dataset into 
a new SPSS file. Descriptive statistics were performed to 
determine the respondent characteristics, place and number 
of  ANC visits, and malaria prophylaxis in pregnancy. Use of  
SP for malaria prophylaxis in pregnancy was cross-tabulated 
with respondent characteristics, place and number of  ANC 
visits, to check for statistical significance. Regression analysis 
was done to identify the determinants of  use of  SP for 
malaria prophylaxis in pregnancy. The independent variables 
included age category, media exposure, geopolitical region, 
place of  residence (urban vs rural), wealth index, place of  
ANC attendance and number of  ANC visits.  
Results
Results are presented in tables 1-4. A total of  38,948 women 
were surveyed. Majority of  them were below 40 years and 
residing in rural areas. More than a third were not educated 
(35.3%); 44.1% were illiterate and more than a quarter (28%) 
had no media exposure (table 1). Antenatal care attendance 
during pregnancy and use of  malaria chemoprophylaxis 
are presented in table 2 below. Out of  the 38,948 women 
surveyed, 20,192 reported that they had given birth in the five 
years preceding the survey and were eligible to be interviewed 
about antenatal care and use of  malaria prophylaxis; no 
response was recorded for 120 of  these eligible women.  
Out of  the 20,072 eligible women who responded, 31% 
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use of  SP. Each variable that potentially predicts the use of  
SP in pregnancy was analyzed independently to generate 
the unadjusted odds ratio while all other variables were 
held constant to generate adjusted odds ratio. The predictor 
variables include age category, exposure to media, type of  
place of  residence, region, wealth index, place of  attendance 
of  ANC and number of  ANC visits. Women in the age 
categories of  20 years and above are more likely to use SP in 
pregnancy than women in 15-19 years age category. Those in 
the 20-34 years age category are 1.3 or more times more likely 
to use SP. Those who are exposed to media are more likely to 
use SP than those who are not. However, exposure to more 
than one source of  media does not make much difference 
in the likelihood of  use of  SP in pregnancy. The regional 
variations show that those in the south are less likely to use 
SP in pregnancy than those in the north. Women residing 
reported they had attended 4 or more ANC visits, while one-
third did not attend ANC at all. The first ANC visit for as 
many as 61.5% of  the women was in the second trimester. 
Majority of  them attended ANC in government facilities - 
hospitals accounted for 43.2% while health centers, posts 
and dispensaries accounted for 35.9%. Almost half  of  the 
women surveyed (49.9%) took no drug for the prevention 
of  malaria in pregnancy. SP was taken by only 25.8% of  
the study population. Demographic and socioeconomic 
factors associated with use of  SP for malaria prophylaxis 
in pregnancy are presented in table 3 below. Statistical 
significant association (p < 0.001) exists between use of  SP 
for malaria prophylaxis in pregnancy and age category, level 
of  education, literacy, region, type of  place of  residence, 
media exposure and wealth index.  Table 4 shows the results 
of  logistic regression analysis of  factors associated with the 
Demographic and socioeconomic variables Frequency (%)







Region North Central 6251 (16.0)
North East 6630 (17.0)
North West 9673 (24.8)
South East 4462 (11.5)
South South 6058 (15.6)
South West 5874 (15.1)




H i g h e s t 
educational 
level









Literacy Cannot read at all 17186 (44.1)
Able to read only parts of 
sentence
2616 (6.7)
Able to read whole sentence 18831 (48.3)
Not assessed 293 (0.8)
Blind/visually impaired 22 (0.1)
* M e d i a 
exposure 
No exposure 10903 (28.0)
Exposure to one source 8305 (21.3)
Exposure to any two sources 12308 (31.6)
Exposure to all three sources 7432 (19.1)
*Reads newspaper, listens to radio, watches television
Variables Frequency (%)
Number of antenatal visits during 
pregnancy
N = 20,072
No antenatal visit 6662 (33.2)
1 – 3 2483 (12.4)
4 1639 (8.2)
>4 8868 (22.8)
Don’t remember 420 (2.1)
Timing of first antenatal check N = 13456
First trimester 3700 (27.5)
Second trimester 8275 (61.5)
Last trimester 1438 (10.7)
Don’t know 43 (0.3)
Place of attendance of ANC N = 13285
Home (respondents’ or others’) 442 (3.3)




Other public sector 4
Private hospital/clinic 2796 (21)
Other private sector 62 (0.5)
Other places 13 (0.1)
Antimalarial drug taken during 
pregnancy
N = 20,110






*Other antimalaria 399 (2.0)
**Other drugs for malaria 1473 (6.8)
*Refers to all other antimalaria drugs that are not less 
commonly used and not listed
**Refers to other drugs that people take for malaria such as 
analgesics, antipyretics, antibiotics, etc
Table 1: Respondent’s characteristics Table 2: Antenatal care and malaria prophylaxis during last 
pregnancy
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years) were 2 times more likely (inverse of  0.68 OR) to take 
SP in pregnancy than those who used private health facilities. 
The number of  ANC visits is a strong predictor of  use of  SP 
for malaria prophylaxis in pregnancy. Those who attended at 
least four ANC visits were 1.46 times more likely to use SP in 
pregnancy than those who attended for less than four times. 
Discussion
Our findings reveal that only 1 in 4 Nigerian women used SP 
for malaria prophylaxis in pregnancy and about half  of  them 
did not receive any other antimalarial drugs for prophylaxis 
in pregnancy in 2013. This implies that malaria infection 
could continue to rank high on the list of  common causes of  
maternal morbidity in Nigeria, necessitating renewed efforts 
on this aspect of  malaria control. This agrees with other 
studies reporting low IPTp coverage13, 15-16, 18. With respect 
to potential effects of  provider behaviour and availability of  
supplies on SP use in pregnancy, it has been reported that 
in urban areas were 1.16 times more likely (unadjusted OR) 
to use SP in pregnancy than women in rural areas. Women 
in richer quintiles were more likely to use SP in pregnancy 
than women in poorer quintiles. The upper three quintiles 
were 1.33 to 1.8 times more likely to receive SP than the 
poorest (adjusted OR). The place of  attendance of  antenatal 
care predicts whether a woman will use SP for malaria 
prophylaxis in pregnancy. Women who received ANC from 
public health facilities in their last live birth (in the past 2 
Demographic, geographic 
and wealth index characteristics
Women who took 











H i g h e s t 
educa t iona l 
level




Literacy Cannot read at all 2421 (21.5) <0.001*
Able to read only 
parts of sentence
453 (32.5)
Able to read 
whole sentence
2268 (31.2)
Not assessed 6 (8.1)
B l i n d / v i s u a l l y 
impaired
1 (14.3)
Region North Central 808 (26.2) <0.001
North East 1140 (28.6)
North West 1678 (27.1)
South East 414 (24.2)
South South 439 (17.7)
South West 701 (26.3)
Type of place 
of residence
Urban 2232 (33.0) <0.001
Rural 2948 (22.1)





M e d i a 
exposure 
No exposure 1323 (19.4) <0.001
Exposed to 1 
source only
1202 (24.8)
Exposed to any 2 
sources
1718 (29.4)













Age category *15-19 0.01
20-24 0.264 0.01 1.30 1 . 0 8 -
1.58
5.37
25-29 0.298 <0.01 1.35 1 . 1 2 -
1.62
7.28
30-34 0.309 <0.01 1.36 1 . 1 3 -
1.64
7.95
35-39 0.211 0.04 1.23 1 . 0 1 -
1.50
6.13
40-44 0.123 0.27 1.31 0 . 9 1 -
1.41
3.40
45-49 0.140 0.33 1.15 0 . 8 7 -
1.52
1.31
M e d i a 
e x p o s u r e 
(newspaper, 
r a d i o , 
television)





s o u r c e 
only




to any 2 
sources




to all 3 
sources
0.103 0.16 1.11 0 . 9 6 -
1.28
1.244
Region * N o r t h 
Central
<0.001
N o r t h 
East
0.603 <0.001 1.83 1 . 6 1 -
2.08
1.40
N o r t h 
West
1.254 <0.001 3.50 3 . 0 7 -
3.99
1.41
S o u t h 
East
-0.275 <0.001 0.76 0 . 6 5 -
0.89
0.69
S o u t h 
South
-0.526 <0.001 0.59 0 . 5 1 -
0.69
0.53
S o u t h 
West
-0.253 <0.001 0.78 0 . 6 8 -
0.89
0.91
Residence *Urban vs 
Rural
-0.002 0.96 0.99 0 . 9 0 -
1.10
0.86**
Table 3: Cross-tabulation of demographic and wealth index 
characteristics with use of SP for IPTp of malaria
Table 4: Logistic regression of factors associated with use of 
SP for malaria prevention in pregnancy
*Fisher’s exact test
           https://doi.org/10.4314/mmj.v32i1.9
Malawi Medical Journal 32 (1): 45-51 March 2020 Malaria Prophylaxis in Pregnancy 49
SP is widely available and relatively affordable at the cost of  
0.06 USD per dose. Counterfeiting was also not an issue as 
most products have provisional approval by the National 
Agency for Food and Drug Administration and Control19. 
Onwujekwe et al also reported in 2012 that private providers 
still administered weekly malaria prophylaxis to pregnant 
women using pyrimethamine, chloroquine and proguanil16. 
Hence, SP was not the only antimalarial drug being used to 
prevent malaria in pregnancy.
The use of  SP for malaria prophylaxis in pregnancy was 
lowest among women ages 15-19 years and above 40 years; 
who are uneducated; illiterate; not exposed to modern sources 
of  media; residing in rural areas; and in the poorest wealth 
quintile. It has been reported that women who are unaware 
of  the benefits of  IPTp or the preventive value of  SP are less 
likely to use it for malaria prophylaxis in pregnancy10. ANC 
provides opportunities for pregnant women to be trained on 
various aspects of  pregnancy and childbirth, including malaria 
prevention. Older and multiparous women are more likely to 
have had more exposures to ANC trainings than younger 
(teenage) and nulliparous women. Hence, it is expected that 
they would have higher utilization rates. However, some 
studies in Nigeria have also reported that women at the upper 
extremes of  reproductive age adhered the least to antenatal 
care although older age and place pregnant women and their 
neonates at higher risks of  morbidity and mortality20-24 . 
Although education, literacy and exposure to modern media 
sources have strong statistical associations with utilization of  
SP for malaria prophylaxis in pregnancy, media exposure is 
the only determinant of  SP use in pregnancy. Community 
media saturation has been reported to increase maternal 
health service utilization25 probably through  creating 
awareness. However, it would be simplistic to conclude that 
media exposure alone has an independent or direct effect on 
service utilization, since the decision to use and the actual 
utilization of  health services is an interaction of  individual, 
social, economic and health service factors26-28. 
The higher the wealth index, the more likely that the women 
used SP for malaria prophylaxis in pregnancy. Also, women 
residing in urban areas were more likely to use SP than those 
in the rural areas. The observed socioeconomic inequity in 
SP use in pregnancy compares well with Dialla et al study 
where income and wealth index had similar effects on the 
use of  SP, but were interpreted as minor barriers when 
compared with provider factors such a stock-out of  drugs29. 
Takem and colleagues, on the other hand, found that in Beua, 
Cameroon, socio economic status did not have any effect on 
the use of  IPTp for malaria30. Although it is expected that 
removal of  user fees for malaria prophylaxis (in pregnancy) 
in public health facilities would reduce the SES inequity in 
access, this may be hampered by frequent stock-out of  drugs 
in primary health centers, necessitating purchase of  SP from 
private providers. The observed inequity in use of  SP by type 
of  place of  residence (urban versus rural), shows persisting 
inequity since the DHS Report of  200813. These persisting 
inequities were also reflected 2 years later in the Malaria 
Indicators Survey of  201531. Several factors could explain 
this difference such as different levels of  access to service 
providers and availability of  information.
Regional differences exist in the use of  SP for malaria 
prophylaxis in Nigeria. However, different from the 
frequently reported relatively lower maternal and child health 
service utilization rates in northern Nigeria32, geopolitical 
regions in the north had better utilization rates than the south. 
Regional variation has been reported in the past concerning 
uptake of  maternal and child health interventions in 
Nigeria33. With respect to use of  SP for malaria prophylaxis 
in pregnancy this variation could be accounted for by the 
fact that far more women in the northern regions than the 
southern regions were reported to have been accessing 
antenatal care from public facilities during the 2013 DHS12. 
The 2015 Malaria Indicator Survey also highlights that the 
proportion of  Nigerians living under conditions of  hyper-
transmission and holoendemic transmission of  malaria 
are in the northern region, and this could also account for 
the higher SP utilization rate31. Practices in private health 
facilities often differ from those in government owned 
health facilities. Mubyazi et al reported that failure to adhere 
to national guidelines for malaria control through IPTp 
was more likely to happen in private health facilities34. For 
instance, they were more likely to charge fees for SP and 
to dispense other antimalarial drugs on the request of  their 
pregnant clients; hence, creating inconsistencies in National 
programme implementation34. 
Whereas the use of  SP in pregnancy differs significantly 
between those who booked at the first and second trimesters, 
there was no significant difference in the use of  SP between 
the first and third or second and third trimester bookings. 
Marginal difference in the use of  SP was also observed, with 
respect to frequency of  ANC visits, between those who had 
less than four visits and those who had at least four visits. 
Place of  attendance of  ANC was seen to be a determinant 
of  IPTp with SP in Nigeria. Women who attended ANC in 
public facilities were more likely to receive SP than those who 
attended ANC in private facilities. This could be because SP 
is given free of  charge to pregnant women attending ANC 
in public health facilities. While this may be the case for most 
regions, Onwujekwe et al reported that women attending 
ANC in private health facilities in South-east Nigeria were 
more likely to receive SP for malaria prophylaxis than those 
attending public facilities16. This could be associated with 
frequent stock-out of  drugs which is commonly experienced 
in public health facilities and has been reported as one of  the 
major factors affecting malaria interventions in Nigeria29, 35-36. 
Wealth index *Poorest <0.001
Poorer 0.05 0.47 1.06 0 . 9 1 -
1.22
1.340**
Middle 0.288 <0.001 1.33 1 . 1 5 -
1.56
1.441
Richer 0.510 <0.001 1.67 1 . 4 1 -
1.97
1.523
Richest 0.587 <0.001 1.80 1 . 4 9 -
2.17
1.404
Place of ANC *Public vs 
Private





*< 4 vs ≥ 
4 visits 
0.38 <0.001 1.46 1 . 3 1 -
1.63
4.18
F i r s t 
a n t e n a t a l 
check
* F i r s t 
trimester
0.01
S e c o n d 
trimester
0.09 0.07 1.09 0 . 9 9 -
1.19
1.21**
T h i r d 
trimester
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The timing of  the first ANC visit and frequency of  visits 
may well affect the use of  SP for malaria prophylaxis in 
pregnancy11, and although Dialla et al reported that attaining 
the recommended number of  ANC visits did not ensure that 
women received at least 2 doses of  IPTp, the difference in 
sample size could explain this observed disparity29. Overall, 
our findings corroborate reports of  substantial missed 
opportunities for administering SP in pregnancy since a 
considerably larger proportion of  women appear to be 
attending ANC than using SP for malaria prophylaxis in 
pregnancy10. 
Although SP prophylaxis is provided free of  charge to 
mothers receiving ANC in public facilities in Nigeria, 
coverage is still poor and inequities in access and use exist. 
Considerable effort is still required by the national and sub-
national malaria control programs to improve coverage of  
IPTp in Nigeria. The widely reported SP resistance in malaria 
endemic areas necessitates that more efficacious antimalarial 
drugs should be used for scaling up IPTp. 
Our study did not evaluate use of  malaria prevention 
strategies such as insecticide-treated bed net which is routinely 
given to pregnant women, and indoor residual spraying 
with insecticides which is gaining coverage in Nigeria. The 
availability/coverage and use of  these preventive strategies10, 
35 may explain the poor utilization of  IPTp among pregnant 
women in the survey. However, this paper cannot report on 
this relationship and this is a limitation of  the study.
Conclusions
Use of  SP for malaria prophylaxis in pregnancy is generally 
low across all demographic groups, socioeconomic groups, 
geographic and geo-political regions in Nigeria. Inequities 
still exist across these categories and those in vulnerable 
population segments (such as teenagers of  reproductive age; 
uneducated women; rural dwellers; women from the poorest 
households) are the least covered. Various ANC utilization 
indicators (such as place of  attendance, timing of  first 
attendance and frequency of  visits) as well as demographic, 
socioeconomic and geographic characteristics (such as age 
category, media exposure, wealth index type of  place of  
residence and region) predict whether a woman will use SP 
for malaria prophylaxis in pregnancy. Thus, interventions to 
scale-up IPTp should be designed to target the least covered 
in order to reduce the existing inequities. 
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